Radiology services provider Radiologix continues to outpace analysts’ revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the company’s ninth
Radiology services provider Radiologix continues to outpace analysts revenue expectations but is still struggling, stockwise. The firm reported revenues of $51.7 million for the fourth quarter (end-December), marking the companys ninth consecutive quarter of revenue growth. Net income for the quarter was $4 million, compared to net income of $3.7 million on revenues of $37.3 million for the same quarter a year ago. Revenues for the year totaled $181 million, a 33% increase over revenues of $135.6 million in 1998. Net income for the quarter rose 19% to $16 million from $13.5 million in 1998.
Despite the increases, the companys stock continues to hover around $4 per share. The stock reached its peak of nearly $9 per share last September following Radiologixs acquisition of Questar (SCAN 8/18/99). That deal made Radiologix (then known as American Physician Partners) one of the largest operators of imaging centers in the U.S., with 118 sites in 18 states and the District of Columbia.
In related news, Radiologix named former senior vice president and COO Mark Martin president of the Dallas-based company. Martin takes over from Mark Wagar, who continues to serve as chairman and CEO.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.